ProfileGDS5678 / 1420343_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 28% 27% 27% 26% 26% 27% 27% 26% 26% 27% 27% 26% 27% 27% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6696228
GSM967853U87-EV human glioblastoma xenograft - Control 22.6146427
GSM967854U87-EV human glioblastoma xenograft - Control 32.6212927
GSM967855U87-EV human glioblastoma xenograft - Control 42.5481226
GSM967856U87-EV human glioblastoma xenograft - Control 52.554826
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6982527
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6566327
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.5927826
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5763326
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6006527
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6030827
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.5763626
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6221827
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6087627